$559 M

DOVA Mkt cap, 11-Oct-2018
Dova Pharmaceuticals Net income (FY, 2016)-27.2 M
Dova Pharmaceuticals EBIT (FY, 2016)-27 M
Dova Pharmaceuticals Cash, 31-Dec-201628.7 M
Dova Pharmaceuticals EV543.9 M

Dova Pharmaceuticals Income Statement

Annual

USDFY, 2016

R&D expense

25.8m

General and administrative expense

1.2m

Operating expense total

27.0m

EBIT

(27.0m)

Income tax expense

152.0k

Net Income

(27.2m)

Dova Pharmaceuticals Balance Sheet

Annual

USDFY, 2016

Cash

28.7m

Current Assets

28.7m

Total Assets

28.7m

Accounts Payable

157.0k

Current Liabilities

8.3m

Long-term debt

13.6m

Total Debt

13.6m

Total Liabilities

22.0m

Common Stock

17.0k

Preferred Stock

1.0k

Additional Paid-in Capital

34.0m

Retained Earnings

(27.2m)

Total Equity

6.8m

Debt to Equity Ratio

2 x

Debt to Assets Ratio

0.5 x

Financial Leverage

4.2 x

Dova Pharmaceuticals Cash Flow

Annual

USDFY, 2016

Net Income

(27.2m)

Accounts Payable

157.0k

Cash From Operating Activities

(987.0k)

Cash From Financing Activities

29.7m

Interest Paid

3.0k

Dova Pharmaceuticals Ratios

USDY, 2016

EV/EBIT

-20.1 x

EV/CFO

-551.1 x

Debt/Equity

2 x

Debt/Assets

0.5 x

Financial Leverage

4.2 x
Report incorrect company information

Dova Pharmaceuticals Operating Metrics

Mar, 2017Jun, 2017

Patents (foreign)

24

Patents Licensed

43

Patents Pending (foreign)

2

Phase III Trials Products

1
Report incorrect company information